Calcineurin inhibitors and cardiac hypertrophy
There has been much debate over whether the immunosuppressive agent, cyclosporin A (CsA), can prevent the development of cardiac hypertrophy. Force et al discuss studies that have found that activated calcineurin (and NF-AT3) could cause hypertrophy and that CsA could prevent this hypertrophy.
Saved in:
Published in | The Lancet (British edition) Vol. 353; no. 9161; pp. 1290 - 1292 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
17.04.1999
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | There has been much debate over whether the immunosuppressive agent, cyclosporin A (CsA), can prevent the development of cardiac hypertrophy. Force et al discuss studies that have found that activated calcineurin (and NF-AT3) could cause hypertrophy and that CsA could prevent this hypertrophy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0140-6736 1474-547X |
DOI: | 10.1016/S0140-6736(99)90016-8 |